DK3909972T5 - Pd1-cd28-fusionsproteiner og disses anvendelse i medicin - Google Patents

Pd1-cd28-fusionsproteiner og disses anvendelse i medicin Download PDF

Info

Publication number
DK3909972T5
DK3909972T5 DK21155542.0T DK21155542T DK3909972T5 DK 3909972 T5 DK3909972 T5 DK 3909972T5 DK 21155542 T DK21155542 T DK 21155542T DK 3909972 T5 DK3909972 T5 DK 3909972T5
Authority
DK
Denmark
Prior art keywords
medicine
fusion proteins
fusion
proteins
Prior art date
Application number
DK21155542.0T
Other languages
Danish (da)
English (en)
Other versions
DK3909972T3 (da
Inventor
Stefan Endres
Sebastian Kobold
Original Assignee
Sebastian Kobold
Endres Stefan Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sebastian Kobold, Endres Stefan Prof Dr filed Critical Sebastian Kobold
Application granted granted Critical
Publication of DK3909972T3 publication Critical patent/DK3909972T3/da
Publication of DK3909972T5 publication Critical patent/DK3909972T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK21155542.0T 2015-06-19 2016-06-20 Pd1-cd28-fusionsproteiner og disses anvendelse i medicin DK3909972T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15172913 2015-06-19
EP16736802.6A EP3310805B1 (en) 2015-06-19 2016-06-20 Pd-1-cd28 fusion proteins and their use in medicine

Publications (2)

Publication Number Publication Date
DK3909972T3 DK3909972T3 (da) 2024-04-29
DK3909972T5 true DK3909972T5 (da) 2024-08-05

Family

ID=53476720

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21155542.0T DK3909972T5 (da) 2015-06-19 2016-06-20 Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
DK16736802.6T DK3310805T3 (da) 2015-06-19 2016-06-20 Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16736802.6T DK3310805T3 (da) 2015-06-19 2016-06-20 Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin

Country Status (13)

Country Link
US (2) US11192935B2 (enExample)
EP (3) EP3310805B1 (enExample)
JP (3) JP7085988B2 (enExample)
CN (3) CN115925971A (enExample)
AU (1) AU2016277883B2 (enExample)
CA (1) CA2989949A1 (enExample)
DK (2) DK3909972T5 (enExample)
ES (2) ES2976647T3 (enExample)
FI (1) FI3909972T3 (enExample)
HU (1) HUE054201T2 (enExample)
PL (1) PL3310805T3 (enExample)
PT (1) PT3310805T (enExample)
WO (1) WO2016203048A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531805A (zh) 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
PT3310805T (pt) * 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
HK1255637A1 (zh) * 2015-06-29 2019-08-23 The Johns Hopkins University 免疫检查点嵌合受体疗法
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药(上海)有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
EP4286522A3 (en) * 2016-03-23 2024-02-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
CN107523545A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
EP3478722A1 (en) * 2016-06-30 2019-05-08 F. Hoffmann-La Roche AG Improved adoptive t-cell therapy
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
WO2018119298A1 (en) * 2016-12-21 2018-06-28 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
EP4043485A1 (en) * 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3595706A1 (en) 2017-03-17 2020-01-22 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
AU2019231205A1 (en) * 2018-03-06 2020-09-24 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
TW202042824A (zh) * 2019-03-27 2020-12-01 賓夕法尼亞大學董事會 Tn-MUC1嵌合抗原受體(CAR)T細胞療法
EP3999079A4 (en) * 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
CN113832114A (zh) * 2020-06-23 2021-12-24 南京大学 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用
CN113832111A (zh) * 2020-06-23 2021-12-24 南京大学 一种类外泌体技术用于制备新型溶瘤病毒的方法
CA3211402A1 (en) * 2021-03-10 2022-09-15 Moshe ELKABETS Reporter cells expressing chimeric polypeptides for use in determining presence and or activity of immune checkpoint molecules
CN120988097A (zh) * 2021-04-11 2025-11-21 中国科学院分子细胞科学卓越创新中心 一种pd1变体及其用途
WO2022246053A2 (en) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Immune checkpoint multivalent particles compositions and methods of use
WO2023235479A1 (en) * 2022-06-02 2023-12-07 TCR2 Therapeutics Inc. Compositions and methods for treating cancer
EP4619424A2 (en) * 2022-11-14 2025-09-24 Achelois Biopharma, Inc. Immune checkpoint multivalent particles compositions and methods of use
WO2025212859A1 (en) * 2024-04-03 2025-10-09 Solid Biosciences, Inc. Methods and constructs for increasing solid organ transplant survival

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19822115B4 (de) 1998-05-08 2004-04-08 Heinrich-Pette-Institut Retrovirale Gentransfervektoren
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 T細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
WO2010012829A1 (en) 2008-07-31 2010-02-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Her2/neu specific t cell receptors
ZA200807283B (en) 2008-08-22 2009-10-28 Mechlift Invest Pty Ltd Data unit for a bin lifting device
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107188969B (zh) 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
PE20141520A1 (es) 2011-07-29 2014-11-17 Univ Pennsylvania Receptores coestimuladores de cambio
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
KR101471647B1 (ko) 2011-10-26 2014-12-11 국립암센터 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물
WO2013062365A2 (ko) 2011-10-26 2013-05-02 국립암센터 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물
CA3209571A1 (en) 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3039040B1 (en) 2013-08-26 2021-12-22 Hinrich Abken Anti cd30 chimeric antigen receptor and its use
BR112017011771A2 (pt) 2014-12-02 2018-07-10 Prospect Chartercare Rwmc Llc métodos e composições para o tratamento de câncer
PT3310805T (pt) 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
WO2019051128A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF
CN115418362B (zh) * 2019-12-02 2025-06-13 吉林凯莱英医药化学有限公司 共固定化酶、其制备方法及其应用

Also Published As

Publication number Publication date
FI3909972T3 (fi) 2024-05-03
ES2976647T3 (es) 2024-08-06
EP4349854A2 (en) 2024-04-10
PT3310805T (pt) 2021-05-19
AU2016277883B2 (en) 2020-09-17
EP3909972A1 (en) 2021-11-17
US20220169699A1 (en) 2022-06-02
US11192935B2 (en) 2021-12-07
EP3310805B1 (en) 2021-02-17
PL3310805T3 (pl) 2021-08-23
AU2016277883A1 (en) 2018-01-18
HUE054201T2 (hu) 2021-08-30
JP2022084787A (ja) 2022-06-07
EP3909972B1 (en) 2024-02-14
CN108026151A (zh) 2018-05-11
EP4349854A3 (en) 2024-07-10
DK3909972T3 (da) 2024-04-29
CA2989949A1 (en) 2016-12-22
US20190010207A1 (en) 2019-01-10
JP7085988B2 (ja) 2022-06-17
CN115927474A (zh) 2023-04-07
WO2016203048A1 (en) 2016-12-22
CN115925971A (zh) 2023-04-07
JP2024073636A (ja) 2024-05-29
JP2018518990A (ja) 2018-07-19
JP7460675B2 (ja) 2024-04-02
EP3310805A1 (en) 2018-04-25
AU2016277883A8 (en) 2018-01-25
DK3310805T3 (da) 2021-05-03
CN108026151B (zh) 2022-07-15
ES2870174T3 (es) 2021-10-26

Similar Documents

Publication Publication Date Title
DK3909972T3 (da) Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
FIC20250034I1 (fi) O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola
DK3368555T3 (da) Dobbeltfunktionsproteiner og farmaceutisk sammensætning omfattende disse
DK3505519T3 (da) Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin
IL262652A (en) Gdf15 fusion proteins and uses thereof
IL254165B (en) Immunomodulatory fusion proteins and uses thereof
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3922279T3 (da) Præparater til lægemiddelafgivelse og anvendelse heraf
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
DK3378859T3 (da) Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
SI3565828T1 (sl) SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
DK3345587T3 (da) Beholderholdeelement og medicinsk beholdersæt
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3354661T3 (da) Fuldstændigt humant antistof mod human CD137 og anvendelse deraf
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
SI3129018T1 (sl) Zdravljenje nafld in nash
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
HRP20190028T1 (hr) Interleukin-2 fuzijski proteini i njihove primjene
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
SI3319612T1 (sl) Oksisteroli in postopki za uporabo le-teh
DK3322734T3 (da) Multivalente og multispecifikke DR5-bindende fusionsproteiner
SI3290441T1 (sl) RGMA-vezavni protein in njegova uporaba
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe